The shares are listed on the Nasdaq Global Select Market

Davis Polk advised the underwriters in connection with the $345 million SEC-registered follow-on offering by Legend Biotech Corporation of 8,615,575 American Depositary Shares, each representing two ordinary shares, which included 1,115,575 ADSs sold pursuant to the underwriters’ over-allotment option. The ADSs are listed on the Nasdaq Global Select Market under the symbol “LEGN.”

Legend Biotech Corporation is a global, clinical-stage biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, Legend Biotech Corporation is developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor, and natural killer cell-based immunotherapy. 

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Ida Araya-Brumskine and Christopher Piazza. Partner Lucy W. Farr and associate Ben Levenback provided tax advice. Partner David R. Bauer and associates Jesse L. Hallock, Marisa Elena Bannon and Hilary Smith provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post